	US 11,904,013 B2
	Immunogenic composition and use thereof
Chih-Hsiang Leng, Taichung (TW); Po-Hsu Su, Taichung (TW); and Po-Kang Chen, Taichung (TW)
Assigned to ADIMMUNE CORPORATION, Taichung (TW)
Filed by ADIMMUNE CORPORATION, Taichung (TW)
Filed on May 3, 2021, as Appl. No. 17/246,740.
Claims priority of provisional application 63/019,442, filed on May 4, 2020.
Prior Publication US 2021/0353742 A1, Nov. 18, 2021
Int. Cl. A61K 39/215 (2006.01); C12N 15/86 (2006.01); C07K 14/005 (2006.01); A61P 31/14 (2006.01); C07K 7/08 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/215 (2013.01) [C07K 7/08 (2013.01); C12N 7/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); C12N 2710/14043 (2013.01); C12N 2770/20034 (2013.01)]

15 Claims

1. A immunogenic composition comprising:

a recombinant protein including a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4; or

a nucleic acid molecule encoding the recombinant protein.